| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 07/10/2001 | US6258843 4-oxy-3-(aryl)phenyl-arylcarbonyloxy compounds useful as phosphodiesterase inhibitors |
| 07/10/2001 | US6258838 Compounds |
| 07/10/2001 | US6258833 Enzyme inhibitors and antiinflammatory agents |
| 07/10/2001 | US6258802 Corticoid therapy |
| 07/10/2001 | US6258800 Prodrugs of benzofuranylethyl carbamate NK1 antagonists |
| 07/10/2001 | US6258790 Antisense modulation of integrin α4 expression |
| 07/10/2001 | US6258580 Amino acid sequence of adaptor protein required for g protein-dependent activation of phosphatidylinositol-3-kinase; drug screening; diagnosis; antiarthritic agents; antiinflammatory agents; adult respiratory distress syndrome |
| 07/10/2001 | US6258562 Human antibodies that bind human TNFα |
| 07/10/2001 | US6258374 Rectal or vaginal administration; polymer stabilizer; water soluble foam structure |
| 07/10/2001 | US6258372 Xylitol nose spray |
| 07/10/2001 | CA2175643C Utilization of retinoids in a cosmetic composition or in the preparation of a pharmaceutical composition |
| 07/10/2001 | CA2139653C Optically pure salts of pyridinylmethyl sulfinyl-ih- benzimidazole compounds |
| 07/10/2001 | CA2069608C Substituted 4-phenyl-4-piperidinecarboxamides with both local anaesthetic and analgesic effect as well as processes for their preparation |
| 07/10/2001 | CA2017135C Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides, processes for their preparation and their use in medicaments |
| 07/05/2001 | WO2001048231A2 Method of achieving persistent transgene expression |
| 07/05/2001 | WO2001048190A2 Therapeutic uses of lna-modified oligonucleotides |
| 07/05/2001 | WO2001048161A2 Human heparanase-related polypeptide and nucleic acid |
| 07/05/2001 | WO2001047963A2 Inhibitors of complement activation, their preparation and use |
| 07/05/2001 | WO2001047930A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 07/05/2001 | WO2001047926A1 Compounds and methods for the treatment of pain |
| 07/05/2001 | WO2001047925A1 Compounds and methods for the treatment of pain |
| 07/05/2001 | WO2001047922A2 Azaindoles |
| 07/05/2001 | WO2001047921A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | WO2001047920A1 Benzazole derivatives and their use as jnk modulators |
| 07/05/2001 | WO2001047915A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047914A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047905A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047897A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | WO2001047895A1 Novel compounds having five-membered hetero-aromatic rings |
| 07/05/2001 | WO2001047892A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | WO2001047891A1 Heterocyclic compounds having sulfonamide groups |
| 07/05/2001 | WO2001047889A1 Tricyclic compounds |
| 07/05/2001 | WO2001047887A1 β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS |
| 07/05/2001 | WO2001047886A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | WO2001047885A1 Substituted indole mannich bases |
| 07/05/2001 | WO2001047880A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047878A1 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 07/05/2001 | WO2001047874A1 (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| 07/05/2001 | WO2001047866A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | WO2001047859A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | WO2001047562A2 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 07/05/2001 | WO2001047559A1 Patches for external use |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047515A1 Use of trimebutine for treating pain |
| 07/05/2001 | WO2001047354A1 Model animal with favorite onset of rheumatoid arthritis |
| 07/05/2001 | WO2001012592A3 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 07/05/2001 | WO2001009094A3 Chemokine receptor antagonists and methods of use therefor |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2001000824A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 07/05/2001 | WO2000078332A3 Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/05/2001 | WO2000073278A3 5-phenyl-pyrimidine derivatives |
| 07/05/2001 | WO2000071679A3 Human oxidoreductase proteins |
| 07/05/2001 | WO2000070046A3 Secreted polypeptides and corresponding polynucleotides |
| 07/05/2001 | WO2000069896A3 Molecular interactions in haematopoietic cells |
| 07/05/2001 | WO2000068195A3 Substituted pyrrolidines as cell adhesion inhibitors |
| 07/05/2001 | WO2000023114A9 Polymer conjugates of interferon beta- 1a and their uses |
| 07/05/2001 | US20010007020 Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 07/05/2001 | US20010006973 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 07/05/2001 | US20010006962 Behavior of biologically active compounds favorably modified by replacing a functional group with an unsaturated fatty derivative, e.g. elaidic acid; bioavailability; membrane passage; organ targeting; drugs; agriculture |
| 07/05/2001 | US20010006940 Human chorionic gonadotrophin (hCG) used to treat or prevent tumors, multiple sclerosis, inflammation or angiogenesis-dependent diseases |
| 07/05/2001 | US20010006686 Extract; antiinflammatory agent for treatment of cyclooxygenase-2 (COX-2) conditions such as arthritis, pain from cancer; selective inhibition of COX-2 over COX-1 |
| 07/05/2001 | US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response |
| 07/05/2001 | DE19963178A1 Substituierte Indol-Mannichbasen Substituted indole Mannich bases |
| 07/05/2001 | CA2699568A1 Azaindoles |
| 07/05/2001 | CA2396693A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | CA2396579A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | CA2396502A1 Substituted pyrrole mannich bases |
| 07/05/2001 | CA2395834A1 Tricyclic compounds |
| 07/05/2001 | CA2395663A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395544A1 Method of achieving persistent transgene expression |
| 07/05/2001 | CA2395543A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395320A1 Therapeutic uses of lna-modified oligonucleotides |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395275A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 07/05/2001 | CA2395179A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | CA2395173A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | CA2394747A1 Use of trimebutine for treating pain |
| 07/05/2001 | CA2394727A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | CA2394098A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | CA2393583A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | CA2393529A1 Inhibitors of complement activation, their preparation and use |
| 07/05/2001 | CA2392866A1 Substituted indole mannich bases |
| 07/05/2001 | CA2392703A1 Human heparanase-related polypeptide and nucleic acid |
| 07/04/2001 | EP1113007A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 07/04/2001 | EP1112381A1 Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
| 07/04/2001 | EP1112368A1 Use of protein kinase kiaa0551 as pharmaceutical |
| 07/04/2001 | EP1112365A2 Human and murine g-protein-coupled edg6 receptor (endothelial differentiation gene) and use of same |
| 07/04/2001 | EP1112361A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 07/04/2001 | EP1112286A1 Secreted proteins and polynucleotides encoding them |
| 07/04/2001 | EP1112265A1 2-arylalkylthio -imidazoles, 2-arylalkenyl -thio -imidazoles and 2-arylalkinyl -thio -imidazoles as anti -inflammatory substances and substances inhibiting the release of cytokine |
| 07/04/2001 | EP1112262A1 SUBSTITUTED $g(g)-PHENYL-$g(D)-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO |
| 07/04/2001 | EP1112255A1 4,4-biarylpiperidine derivatives with opioid receptor activity |
| 07/04/2001 | EP1112253A1 Branched alkyl pyrrolidine-3-carboxylic acids |
| 07/04/2001 | EP1112079A1 Myrtle extract, preparation method and use |
| 07/04/2001 | EP1112078A2 New use |
| 07/04/2001 | EP1112073A1 Calcilytic compounds |
| 07/04/2001 | EP1112070A1 Novel substituted triazole compounds |
| 07/04/2001 | EP0850236B1 Piperazino derivatives as neurokinin antagonists |
| 07/04/2001 | EP0814776B1 Topically applied pharmaceutical composition, method of preparing it and its use |